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• Column: HALO C18 (4.6×150 mm, 2.7 µm) + guard 
• Mobile phase A: 0.1% glacial acetic acid in H2O 
• Mobile phase B: 0.1% glacial acetic acid in ACN 
• Column / sample compartment temp.: 30 C / 15 C 
• Injection volume: 10 µl 
• Detection: PDA 190-400 nm, detection @ 240 nm 
 
EXPERIMENTAL  
[1] M. D’Hondt, E. Vangheluwe, S. Van Dorpe, et al. Stability of ex-tempore prepared Triple intrathecal solution consisting of cytarabine, methotrexate and methylprednisolone 
sodium succinate. American Journal of Health-System Pharmacy, submitted for publication. 
RESULTS and DISCUSSION  
The development of a stability-indicating high-throughput HPLC method for three Triple IT components (CB, MTX and MPSS) was done using a fused-
core (HALO®) stationary phase. 
• 15 min. gradient    separation of individual components and related degradation products. 
• Method verification  HPLC method fit for use in a short-term Triple IT storage stability protocol. 
CONCLUSIONS 
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# Time (min.) 
Flow rate 
(ml/min) 
%A %B Remarks 
1 Different time 
intervals 
(5 to 30 min.) 
1 
90 10 
Analysis 
2 10 90 
3 3 min. 90 10 Column rinsing + 
equilibration 
4 12 min. 90 10 
HPLC parameters: Gradient program: Solutions: 
• Individual components unstressed 
• Individual components stressed: 
 (40 C and 80 C, up to 29 hrs.) 
• Mixture of components unstressed 
• Mixture of components stressed: 
 (40 C and 80 C, up to 29 hrs.) 
Mixture of components unstressed: 5 C, 29 hrs. 
Mixture of components stressed: 80 C, 29 hrs. 
CB 
MTX 
MPSS 
• Single HPLC method capable of separating the three 
 structurally different Triple IT components. 
• Fast separation (total run time = 30 min): 
 Reduction of solvent, time and hardware consumption 
• Sufficient resolution between individual components and 
 related degradation products. 
• Peak purity analyses suggests pure peaks: 
 (Triple IT components and related degradants) 
Parameter CB MTX MPSS 
Linearity 
(R²; 80-100-120% l.c.) 
1.0000 0.9992 1.0000 
Repeatability 
(%RSD; 100% l.c.; n = 3) 
0.464 1.352 0.155 
LoQ 
(% l.c.) 
0.03 0.07 0.05 
CB:   280 nm 
MTX:  280 nm 
MPSS:  240 nm 
For the majority of children with acute lymphoblastic leukemia (ALL), prophylactic treatment of the central nervous system 
consists in part of a triple intrathecal (Triple IT) therapy, i.e. a combination of cytarabine (CB), methotrexate (MTX) and 
methylprednisolone sodium succinate (MPSS). This combination product is prepared ex-tempore. However, no in-use shelf-
life under defined storage conditions has yet been established. During these stability studies, a large number of samples are 
generated, thus creating the need for a fast, accurate and selective analytical method. Newly developed fused-core HPLC 
stationary phases (HALO® columns) are suited for these high-throughput purposes. Due to their small particle size and 
unique particle technology, with 0.5 µm porous shell fused to a solid core particle, these columns allow fast and high 
performance separations. Subsequently, this new column technology was chosen for the development of a stability-
indicating HPLC method to be used during a short-term stability study of the Triple IT solution [1]. 
 Objective  (i) development of stability-indicating HPLC-method and (ii) method evaluation. 
